Mighty Therapeutics Launches New Studies for MYTX-255, a Cutting-Edge Mitochondrial Treatment#United_States#Needham#Mighty_Therapeutics#MYTX-255#mitochondrial_dysfunction
Mighty Therapeutics Launches New Studies for MYTX-255, a Cutting-Edge Mitochondrial Treatment
Mighty Therapeutics embarks on IND-enabling studies for MYTX-255, a groundbreaking therapeutic targeting mitochondrial dysfunction in severe diseases. The company aims for IND submission in 2027.
third-news.com
September 9, 2026 at 1:21 PM
Mighty Therapeutics Launches New Studies for MYTX-255, a Cutting-Edge Mitochondrial Treatment#United_States#Needham#Mighty_Therapeutics#MYTX-255#mitochondrial_dysfunction
Mighty Therapeutics and University of Washington Achieve Milestone in XPRIZE Healthspan Competition#United_States#Needham#XPRIZE#UW#Mighty_Therapeutics
Mighty Therapeutics and University of Washington Achieve Milestone in XPRIZE Healthspan Competition
Mighty Therapeutics, in collaboration with the University of Washington, has been awarded in the XPRIZE Healthspan competition for innovative research on aging and health.
third-news.com
August 11, 2026 at 1:52 PM
Mighty Therapeutics and University of Washington Achieve Milestone in XPRIZE Healthspan Competition#United_States#Needham#XPRIZE#UW#Mighty_Therapeutics
Mighty Therapeutics Raises Up to $150 Million for Innovative Mitochondrial Medicines Development#USA#Needham#Elamipretide#K2_HealthVentures#Mighty_Therapeutics
Mighty Therapeutics Raises Up to $150 Million for Innovative Mitochondrial Medicines Development
Mighty Therapeutics has secured up to $150 million in financing to advance its novel mitochondrial-targeted therapies, addressing major health challenges.
third-news.com
July 14, 2026 at 12:34 PM
Mighty Therapeutics Raises Up to $150 Million for Innovative Mitochondrial Medicines Development#USA#Needham#Elamipretide#K2_HealthVentures#Mighty_Therapeutics
Mighty Therapeutics Begins Phase 4 Study for Elamipretide in Barth Syndrome Patients#United_States#Needham#Barth_Syndrome#Elamipretide#Mighty_Therapeutics
Mighty Therapeutics Begins Phase 4 Study for Elamipretide in Barth Syndrome Patients
Mighty Therapeutics has launched a Phase 4 study examining the efficacy of elamipretide for Barth syndrome, marking a significant milestone in patient treatment options.
third-news.com
July 8, 2026 at 12:27 PM
Mighty Therapeutics Begins Phase 4 Study for Elamipretide in Barth Syndrome Patients#United_States#Needham#Barth_Syndrome#Elamipretide#Mighty_Therapeutics
Mighty Therapeutics: A New Era in Mitochondrial Disease Treatment and Advocacy#USA#Needham#Barth_Syndrome#FORZINITY#Mighty_Therapeutics
Mighty Therapeutics: A New Era in Mitochondrial Disease Treatment and Advocacy
Mighty Therapeutics, formerly Stealth BioTherapeutics, embraces its new name to celebrate the mitochondrial disease community, focusing on hope and innovative treatments.
third-news.com
June 16, 2026 at 12:27 PM
Mighty Therapeutics: A New Era in Mitochondrial Disease Treatment and Advocacy#USA#Needham#Barth_Syndrome#FORZINITY#Mighty_Therapeutics